

ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa) (“Aspen Holdings”)
Registration number: 1985/002935/06
Share code: APN
ISIN: ZAE000066692
LEI: 635400ZYSN1IRD5QWQ94
and its subsidiaries (collectively “Aspen” or “the Group”)

FINAL COMPLETION OF THE DIVESTMENT OF THE EUROPEAN THROMBOSIS BUSINESS TO MYLAN/VIATRIS

Aspen is pleased to confirm that the divestment of the European Thrombosis Assets¹ (the “Assets”) by its wholly owned subsidiary, Aspen Global Incorporated (“AGI”) to Mylan Ireland Limited (“Mylan/Viatris”) for a total purchase consideration of EUR 641.9 million, plus the cost of the related inventory (the “Transaction”), as announced on 8 September 2020, has now been completed in full.

The disposal of the Assets comprised the following elements relating exclusively to the Products² in Europe:

- intellectual property required for their commercialisation, and any related goodwill owned by AGI and its subsidiaries³;
- product registrations and marketing authorisations; and
- the related inventory.

Aspen received an upfront cash consideration of EUR 263.2 million upon closure of the Transaction at the end of November 2020. The second tranche of the purchase consideration, an amount of EUR 378.7 million, was received on 25 June 2021.

Durban
1 July 2021

Sponsor
Investec Bank Limited

¹ Excludes Russia and the other Commonwealth of Independent States countries.

² The brand names, and variations of the brand names, Arixtra, Fraxiparine, Mono-Embolex and Orgaran in Europe.

³ Excluding certain goodwill relating to distribution of the Products in France.